Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + pemetrexed + bevacizumab versus camrelizumab + pemetrexed + carboplatin as first-line treatment for driver gene-negative advanced nonsquamous non-small cell lung cancer
ChiCTR2000041214Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Nov 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of camrelizumab, pemetrexed, bevacizumab and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: progression-free survival. Started Nov 2020; status: recruiting.
02
Drugs
camrelizumabpemetrexedbevacizumabcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000041214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041214.